We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Non-Invasive Saliva Test Predicts Future Risk for Alzheimer's

By LabMedica International staff writers
Posted on 21 Nov 2022

The risk of developing Alzheimer’s disease has several components; depending on an individual’s genes, he or she may have been born with a higher or lower risk of developing the disease. More...

This genetic risk, which includes an individual’s sex, remains constant, but getting older increases the risk for everyone. Other external factors can also contribute to the risk of developing Alzheimer’s disease and its subsequent progression. Fortunately, there are many positive steps that one can take that have the potential to delay the onset of Alzheimer’s disease, but it is important to understand the risk first. Now, a new non-invasive test can predict the risk of an individual developing Alzheimer’s disease from a simple saliva sample.

Cytox Ltd.’s (Oxford, England) genoSCORE-LAB is a genetic test that analyzes patient genotypes generated from an array of over 100,000 single nucleotide polymorphisms – common genetic variations - that are associated with, or protective against, the risk of developing Alzheimer’s disease. More specifically genoSCORE-LAB generates a polygenic risk score – generated through an algorithm, assessing multiple genetic loci and their associated disease-causing weights, alongside age and sex, which also affect risk. APOE status remains a major genetic component of risk in Alzheimer’s disease, especially carriers of the -E4 allele. However, genoSCORE-LAB provides additional information on the genetic risk of cognitive decline in the E4 heterozygote and E3 homozygote groups. genoSCORE-LAB will also report on APOE status, and highlight presence of gene variants known to be associated with Early Onset Alzheimer's disease.

genoSCORE-LAB only requires a blood or saliva sample. An easy-to-use mouth swab enables individuals to provide a sample from home if they are self-isolating due to COVID-19, or not wishing or easily able to attend a healthcare setting. Initial applications will be for physicians assessing new patients, with cognitive complaints, to better understand their future risk of cognitive decline due to Alzheimer’s disease. It can also provide greater insight into the risk of cognitive decline in existing patients. Additionally, genoSCORE-LAB will be used in clinical study recruitment strategies to identify patients most suitable to enter trials of investigational Alzheimer’s drugs, including those patients with mild cognitive impairment who are most at risk of subsequent decline within the timescale of the study.

Related Links:
Cytox Ltd. 


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
New
Staining System
RAL DIFF-QUIK
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.